Omega-3 Ethyl Esters

ApprovedSmall molecule

UUniversity of Missouri-Columbia

Omega-3 Ethyl Esters is one of 64 small molecule programs targeting Delirium. It is currently in Approved.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

DeliriumActive, not recruiting

Type 2 DiabetesActive, not recruiting

DeliriumPhase 2

Active, not recruiting

Type 2 DiabetesApproved

Active, not recruiting

Competition

Competitive Landscape

885 competitors in Type 2 Diabetes

#DrugCompanyPhaseTrials

Omega-3 Ethyl Esters

UUniversity of Missouri-Columbia

Approved

1 2

Byetta

AstraZeneca

Preclinical

55 3

Jardiance

Boehringer Ingelheim

Preclinical

31 4

NOVOLIN R

Novo Nordisk

Preclinical

5 5

Glargine

Eli Lilly

Preclinical

8 6

Inspra

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Preclinical

2 7

Aurlumyn

BBTG International Inc.

Preclinical

1 8

Nexium

DDexcel Pharma Technologies Ltd.

Preclinical

1 9

Inderal

WWyeth-Lederle Vaccines

Preclinical

1 10

Pravachol

KKaruna Therapeutics, Inc., a Bristol Myers Squibb company

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2037

Post-ApprovalActive, not recruiting

Cardiovascular Events

NCT00135226

Clinical

Trials by Indication[1]

Cardiovascular Events1 trial

ASCEND: A Study of Cardiovascular Events iN Diabetes

Active, not recruiting·UUniversity of Oxford·Phase 4·NCT00135226·15,480 enrolled

Type 2 Diabetes1 trial

Lovaza® and Microvascular Function in Type 2 Diabetes

Completed·—·Phase 4·NCT00931879·44 enrolled

Delirium1 trial

The Effect of Omega 3 Supplementation on Postoperative Delirium in Elderly Patients Undergoing Major Cardiac Surgery

Enrolling by invitation·UUniversity of Missouri-Columbia·Phase 2·NCT06434948·90 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for Omega-3 Ethyl Esters. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Omega-3 Ethyl Esters compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Omega-3 Ethyl Esters. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — University of Missouri-Columbia company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: UUniversity of Missouri-Columbia

Omega-3 Ethyl Esters

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2037

Trials by Indication[1]

Cardiovascular Events1 trial

Type 2 Diabetes1 trial

Delirium1 trial

References

Drug Info

Quick Facts

Related News